ORCHIDPHAR

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the company has isseud a press release in respect of the issue of Global Depository Receipts (GDR's) and Foreign Currency Convertible Bonds (FCCB's) aggregating US$ 75 million. The said securities is proposed to be listed in the Luxembourg Stock Exchange. The details of the press shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Company has issued a press release dated October 13, 2005 titled 'Orchid's Q2 net zooms by 587%; Step function increases in turnover and profitability with regulated market thrust'. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release being issued on October 04,2005 in respect of the company's exclusive marketing alliance with Mayne Pharma to market select life-saving injectable antibiotic formulation in the US,Canada,European and Australasian geographies. The details of the press release titled 'Orchid enters into exclusive marketing alliance with Mayne Pharma ; Broad-based global alliance covering select niche injectable products' shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcement

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Company has received the formal approval from the USFDA for its generic Abbreviated New Drug Application (ANDA) for its formulation product Ceftriaxone for Injection USP, in 250 mg, 500 mg, 1 gm and 2 gm single-dose vials, 1 gm and 2 gm piggyback vials and 10 gm/100 ml pharmacy bulk package vials. The approval of USFDA for the ANDA enables the Company to launch the product in the US. The details of the press release issued by the Company regarding the same shall be available on the NSE website (http://www.nseindia.com) u

Orchid Chemicals & Pharmaceuticals Ltd has submitted to the Exchange a copy of the press release issued by the Company pursuant to the meeting of the BOD's of the Company held on July 18, 2005. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release being issued on June 29,2005 by the company in respect of approval received by the company from the USFDA for its ANDA(Abbreviated New Drug Application) of Cephalexin capsules USP 250 mg and 500 mg. The company has further informed that this is the first ANDA approval received by the company in the oral formulations segments in the US . The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Com

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that a press release dated June 06, 2005, is being issued by the Company in respect of the Company's Research & Development (R&D) centre located in Chennai, which has received the Good Laboratory Practices (GLP) certification. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the company has issued a press release dated April 27, 2005 titled 'Orchid registers turnover of Rs 689 crore during 2004-05 - Net profit at Rs 31 crore'. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that a press release dated March 16, 2005, is being issued by the Company in respect of an exclusive agreement entered with M/s. STADA Pharmaceuticals, Inc. (STADA), the U.S. subsidiary of STADA Arzneimittel AG, for the development and supply of six prescription generic drug products to STADA for the US market. Through this agreement, Orchid will develop and exclusively manufacture these non-cephalosporin formulations for exclusive distribution and marketing by STADA in the US market. The details of the press release shall be av

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Company has issued a press release dated March 07, 2005, in respect of the Company's generic formulations facility located at Irungattukottai inspected by USFDA. The inspection covered the full spectrum of oral and sterile formulation manufacturing blocks and nine Abbreviated New drug Applications (ANDAs) each spanning 4 dosage forms of sterile injectables, tablets, capsules and dry powder syrups. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest A

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Company has issued a press release dated February 24, 2005, in respect of the Company's exclusive pact with Alpharma Inc. to market oral non-antibiotic formulations in the US and European markets. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the company has issued a press release dated January 20, 2005 titled 'Orchid registers turnover of Rs.172 crore during Q3 FY 2004-05 '. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Company is issuing a press release on September 23, 2004, in respect of the Company's US drug discovery joint venture, Bexel Pharmaceuticals, which has been working on a novel anti-diabetic molecule (BLX-1002), has successfully completed limited proof-of-concept Phase 2(a) clinical trials. The patent application filed for this novel molecule (BLX-1002) by Bexel, in the US patent office has been granted. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > La